Tag
This article reviews real-world data supporting homologous recombination deficiency (HRD) testing in BRCA1/2 wild-type high-grade serous carcinoma and examines MYC amplification as a promising surrogate biomarker to guide PARP inhibitor the
This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of s
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demon
The AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improves progression-free survival in HRR-deficient metastatic prostate cancer, with maintained quality of life and manageable safet
Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment ac
Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant...